CLTCL1

Across TCGA pan-cancer cohorts, CLTCL1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of CLTCL1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where CLTCL1 RNA is repressed in tumor relative to normal tissue. In most cancer types CLTCL1 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

THCA, LIHC, and COAD are the cancer types where CLTCL1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CLTCL1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	IV	−1.355	<.001	11	view →
LIHC	Male	All	+0.985	<.001	9	view →
COAD	Female	All	+0.480	<.001	8	view →
KIRC	Female	All	+0.417	<.001	7	view →
BRCA	All	All	−0.485	<.001	6	view →
LUSC	Male	All	+0.897	<.001	5	view →
READ	All	II,III,IV	+0.597	.001	5	view →
HNSC	Female	All	+0.795	.014	3	view →
CHOL	Male	All	+0.668	.031	2	view →
BLCA	All	All	+0.611	.025	2	view →
KICH	Female	II,III,IV	+0.425	.006	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

CLTCL1–THCA

Open the THCA breakdown →